GlassScriptPhysician profile
Molly B Thomas
NPI 1922209139
$12,189.09
in general payments reported to CMS, 2019-2025
65 companies · $3,204 in 2025
The $3,204 reported for 2025 was more than what 75% of Hematology & Oncology providers received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $751 · 2020: $1,922 · 2021: $1,318 · 2022: $729 · 2023: $1,825 · 2024: $2,440 · 2025: $3,204.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,468.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,468.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $2,485.31 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $907.57 | 2019-2025 | Calquence, Imfinzi, Enhertu |
| Daiichi Sankyo INC. | $786.20 | 2019-2025 | Enhertu, Injectafer, Datroway |
| Merck Sharp & Dohme LLC | $727.50 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $595.92 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $509.28 | 2019-2025 | Opdivo, Opdualag, Augtyro |
| Celgene Corporation | $497.09 | 2019-2025 | Reblozyl, Pomalyst, Opdualag |
| Janssen Biotech, INC. | $464.56 | 2020-2025 | Darzalex, Tecvayli, Talvey |
| Gilead Sciences, INC. | $347.88 | 2022-2025 | Trodelvy |
| Genzyme Corporation | $337.89 | 2020-2025 | |
| Incyte Corporation | $287.00 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Genentech USA, INC. | $219.26 | 2019-2025 | Itovebi, Venclexta, Phesgo |
| Eisai INC. | $204.11 | 2020-2025 | |
| Exelixis INC. | $203.03 | 2021-2025 | Cabometyx |
| Bayer Healthcare Pharmaceuticals INC. | $190.42 | 2019-2025 |
Show all 65 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Takeda Pharmaceuticals U.S.A., INC. | $165.59 | 2020-2025 | Ninlaro, Fruzaqla |
| Glaxosmithkline, LLC. | $159.06 | 2020-2025 | Zejula, Jemperli |
| Abbvie INC. | $157.60 | 2022-2025 | |
| Lilly USA, LLC | $147.89 | 2021-2024 | Verzenio, Jaypirca, Retevmo |
| Sobi, INC | $141.31 | 2024-2025 | |
| Amgen INC. | $139.81 | 2019-2024 | Blincyto, Kyprolis, Lumakras |
| Beigene USA, INC. | $134.92 | 2020-2024 | Brukinsa |
| Astellas Pharma US INC | $118.71 | 2019-2025 | Xtandi, Xospata, Vyloy |
| Pharmacyclics LLC, An Abbvie Company | $113.82 | 2021-2023 | Imbruvica |
| Springworks Therapeutics, INC. | $113.20 | 2024-2025 | Ogsiveo |
| Alexion Pharmaceuticals, INC. | $102.93 | 2019-2025 | Ultomiris |
| Ipsen Biopharmaceuticals, INC | $99.67 | 2024-2025 | Somatuline Depot, Onivyde |
| Stemline Therapeutics INC. | $99.54 | 2024-2025 | Orserdu |
| Blueprint Medicines Corporation | $97.03 | 2020-2023 | Ayvakit |
| Seagen INC. | $95.38 | 2021-2023 | Adcetris, Tukysa |
| Emd Serono, INC. | $94.82 | 2021-2025 | Bavencio |
| Karyopharm Therapeutics INC. | $93.95 | 2020-2024 | Xpovio |
| Genmab U.S., INC. | $93.71 | 2023-2024 | Epkinly, Tivdak |
| Jazz Pharmaceuticals INC. | $91.95 | 2020-2024 | |
| Adc Therapeutics America, INC. | $86.16 | 2022-2024 | |
| Aveo Pharmaceuticals, INC. | $84.42 | 2021-2025 | |
| Agios Pharmaceuticals, INC. | $81.41 | 2019-2025 | Pyrukynd |
| Array Biopharma INC | $78.65 | 2024-2025 | Braftovi, Lorbrena, Mektovi |
| Taiho Oncology, INC. | $77.19 | 2023-2025 | Inqovi, Lonsurf |
| Servier Pharmaceuticals LLC | $72.64 | 2024-2025 | |
| Regeneron Healthcare Solutions, INC. | $72.52 | 2021-2025 | Libtayo |
| Kite Pharma, INC. | $70.90 | 2020-2023 | Yescarta |
| Mirati Therapeutics, INC. | $50.92 | 2023-2024 | Krazati |
| Puma Biotechnology, INC. | $47.22 | 2019-2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $35.42 | 2019-2023 | Gilotrif |
| Beone Medicines USA, INC. | $34.10 | 2025 | Brukinsa |
| Alnylam Pharmaceuticals INC. | $32.11 | 2025 | Givlaari |
| Dendreon Pharmaceuticals LLC | $30.77 | 2019-2024 | Provenge |
| Rigel Pharmaceuticals, INC. | $27.68 | 2021-2023 | Rezlidhia, Tavalisse |
| Menarini Silicon Biosystems, INC. | $25.20 | 2025 | |
| Amag Pharmaceuticals, INC. | $25.03 | 2019-2021 | |
| G1 Therapeutics, INC. | $24.57 | 2022-2023 | Cosela |
| Clovis Oncology, INC. | $19.82 | 2020-2021 | |
| Apellis Pharmaceuticals, INC. | $18.84 | 2021 | |
| Ethicon US, LLC | $18.23 | 2019 | |
| Azurity Pharmaceuticals, INC. | $17.94 | 2024 | Vivimusta |
| Myriad Genetic Laboratories, INC. | $17.75 | 2023 | Myrisk |
| Progenics Pharmaceuticals, INC. | $16.81 | 2021 | |
| Veracyte, INC. | $15.94 | 2024 | |
| Verastem, INC. | $15.63 | 2020 | |
| Morphosys, US INC. | $15.09 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $14.75 | 2021 | |
| Tesaro, INC. | $13.13 | 2019 | |
| Teva Pharmaceuticals USA, INC. | $12.47 | 2020 | |
| Cti Biopharma Corp. | $11.87 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Molly Thomas listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.